Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2009

View Archived Issues

ZymoGenetics divulges novel antipsoriatic ztnfr14 antagonists

New humaneered anti-factor B antibodies reported in recent Taligen patent

GSK reports novel AMPA receptor modulators with antipsychotic properties

Recent Merck & Co. patent discloses a new series of polypeptides with antibacterial properties

New Chlamydia vaccine patented by the Thrombosis Research Institute

UCB and Wilex sign strategic alliance to develop UCB's preclinical oncology portfolio

Array BioPharma initiates phase I clinical trial for MEK inhibitor ARRY-300

TopiGen reports phase II TPI-ASM-8 results in asthma patients

Cara commences phase II proof-of-concept trial in acute postoperative pain

Cytokinetics presents update on muscle biology research and development programs

Genzyme and Isis commence several mipomersen trials

Solace initiates phase IIa glial cell modulator trial in postherpetic neuralgia

InterMune reports results from ITMN-191 triple combination study

Ardea presents positive results from phase I RDEA-594 study

Synvista Therapeutics progresses phase II clinical trial program for alagebrium

Clinical investigation of Diasome's hepatic-directed vesicle-insulin advances

Mechanism behind leptin resistance clarified, possible treatments tested in vivo

FK-1706 shows promise in painful diabetic neuropathy

Cubist and Alnylam form strategic collaboration for RNAi therapeutics targeting RSV

Medtronic to acquire Ablation Frontiers for USD 225 million

Esteve signs research partnership for development of AIDS vaccine

Pharmasset and Roche agree with FDA on final design of phase IIb trial of R-7128 in HCV

ISMB authorizes completion of BioLineRx's phase I/II study of BL-1040 in MI

Novartis initiates dosing in phase IIb trial of Albuferon in chronic hepatitis C

Anthera completes enrollment and dosing in FRANCIS clinical trial of varespladib for ACS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...